PMID- 1313443
OWN - NLM
STAT- MEDLINE
DCOM- 19920504
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 89
IP  - 4
DP  - 1992 Apr
TI  - Isoform-specific regulation of platelet-derived growth factor activity and 
      binding in osteoblast-enriched cultures from fetal rat bone.
PG  - 1076-84
AB  - In osteoblast-enriched cultures from fetal rat bone, the A-chain homodimer of 
      platelet-derived growth factor (PDGF-AA) is less potent than the PDGF isoforms 
      containing B chain subunits (PDGF-AB and PDGF-BB), but normal osteoblasts appear 
      to synthesize only PDGF-A subunit mRNA and polypeptide. However, other agents may 
      regulate PDGF-AA activity in skeletal tissue. Pretreatment of osteoblast-enriched 
      cultures with interleukin 1 alpha (IL-1 alpha) or tumor necrosis factor-alpha 
      (TNF-alpha) synergistically enhanced the mitogenic effect of PDGF-AA coincident 
      with increased binding site occupancy, but neither factor augmented PDGF-BB 
      activity or binding. Polyacrylamide gel analysis showed 125I-PDGF-AA binding 
      complexes predominantly at greater than 200 kD and faint labeling at 185 kD. 
      After IL-1 alpha or TNF-alpha pretreatment, PDGF-AA binding increased at both 
      sites, but this effect was more striking at 185 kD, which co-migrated with 
      125I-PDGF-BB-labeled complexes. PDGF-AA binding sites were rapidly lost by 
      comparison to those for PDGF-BB in cycloheximide-treated cultures, but they 
      remained relatively enhanced by IL-1 alpha and TNF-alpha pretreatment. These 
      studies indicate that IL-alpha and TNF-alpha increase PDGF-AA binding and 
      activity for osteoblasts by mechanisms that are at least in part independent of 
      new receptor synthesis, and suggest regulatory events that could control how PDGF 
      binding sites specifically recognize different ligands.
FAU - Centrella, M
AU  - Centrella M
AD  - Department of Research, Saint Francis Hospital and Medical Center, Hartford, 
      Connecticut 06105.
FAU - McCarthy, T L
AU  - McCarthy TL
FAU - Kusmik, W F
AU  - Kusmik WF
FAU - Canalis, E
AU  - Canalis E
LA  - eng
GR  - AR-21707/AR/NIAMS NIH HHS/United States
GR  - AR-39201/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Interleukin-1)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - DNA/biosynthesis
MH  - Female
MH  - Interleukin-1/pharmacology
MH  - Osteoblasts/*drug effects/metabolism
MH  - Platelet-Derived Growth Factor/metabolism/*pharmacology
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Cell Surface/analysis/*metabolism
MH  - Receptors, Platelet-Derived Growth Factor
MH  - Tumor Necrosis Factor-alpha/pharmacology
PMC - PMC442963
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
PMCR- 1992/04/01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
PHST- 1992/04/01 00:00 [pmc-release]
AID - 10.1172/JCI115687 [doi]
PST - ppublish
SO  - J Clin Invest. 1992 Apr;89(4):1076-84. doi: 10.1172/JCI115687.